Among the 19 genes, TOP2A showed a higher expression value and higher CNV values in breast cancer cells sensitive to doxorubicin than those in the resistant cells, while S100P and S100A4 showed lower expression values and lower CNV values in the sensitive cells than those in the resistant ones. This evidence concerns the gene S100A4 and breast cancer.